Persistence of oncolytic Coxsackie virus A7 in subcutaneous human glioblastoma xenografts in mice in the context of experimental therapy

Sidorenko, A. S.; Zheltukhin, Andrei O.; Le, Ting; Soboleva, A.V.; Lipatova, Anastasiya V.; Golbin, Denis A.; Chumakov, Peter M.

doi:10.24075/brsmu.2018.032

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intriguingly, some enteroviruses have also demonstrated a peculiar feature in interfering with tumor progression [ 105 , 106 ]. Voroshilova’s successors have elaborated further on this finding and exploited Coxsackievirus, ECHO type 1 and ECHO type 2 viruses and type 1 poliovirus as oncolytic agents [ 107 ]. Coxsackievirus B6 (LEV-15L strain) has been patented as an efficient treatment against HPV-negative cervical cancer (RU 2496873).…”

Section: Oncolytic Viruses In Clinical Trialsmentioning

confidence: 99%

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

Malogolovkin

Gasanov

Egorov

et al. 2021

Viruses

View full text Add to dashboard Cite

Recent cancer immunotherapy breakthroughs have fundamentally changed oncology and revived the fading hope for a cancer cure. The immune checkpoint inhibitors (ICI) became an indispensable tool for the treatment of many malignant tumors. Alongside ICI, the application of oncolytic viruses in clinical trials is demonstrating encouraging outcomes. Dozens of combinations of oncolytic viruses with conventional radiotherapy and chemotherapy are widely used or studied, but it seems quite complicated to highlight the most effective combinations. Our review summarizes the results of clinical trials evaluating oncolytic viruses with or without genetic alterations in combination with immune checkpoint blockade, cytokines, antigens and other oncolytic viruses as well. This review is focused on the efficacy and safety of virotherapy and the most promising combinations based on the published clinical data, rather than presenting all oncolytic virus variations, which are discussed in comprehensive literature reviews. We briefly revise the research landscape of oncolytic viruses and discuss future perspectives in virus immunotherapy, in order to provide an insight for novel strategies of cancer treatment.

show abstract

Section: Oncolytic Viruses In Clinical Trialsmentioning

confidence: 99%

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

Malogolovkin

Gasanov

Egorov

et al. 2021

Viruses

View full text Add to dashboard Cite

show abstract

“…A different approach consists of selecting those viruses that are known to have good biosafety profiles and are easy to work with. In this respect, the vaccinia virus and as well as coxsackie virus have attracted a considerable attention [19,25,26,[28][29][30]. Combining these two practical themes, several Russian groups have focused their efforts on adenoviruses as arguably the most promising candidates for virotherapy [31,32].…”

Section: Diversity Of Viruses As the Basis For The Development Of New Ovsmentioning

confidence: 99%

Oncolytic Viruses in Tumor Therapy: The Russian Perspective

Nm¹,

Pestov²,

Jm³

et al. 2021

Preprint

View full text Add to dashboard Cite

The idea of using the lytic power of viruses against the malignant cells has been entertained for many decades. However, oncolytic viruses (OV) gained broad attention as an emerging anti-cancer therapy only recently with the successful implementation of the oncolytic herpesvirus to treat advanced melanoma. OVs offer an attractive therapeutic combination of tumor-specific cell lysis together with immune stimulation, yet the latter effect is less well studied. Nevertheless, OVs can be envisaged as potential in situ tumor vaccines. The therapeutic potential of OVs can be instigated further by using the molecular biological and biotechnological tools to modify the existing viruses for their optimal tumor selectivity and enhanced immune stimulation. Furthermore, OVs can be readily combined with other therapeutic agents to increase the efficacy of the existing therapeutic schemes. In this review, we discuss biotechnological advances in the development of therapeutic applications of OVs in Russia. Particular emphasis is made on the OV-mediated treatment of glioblastoma. In addition, we highlight the challenges of oncolytic virotherapy, and describe the strategies to optimize current approaches to improve clinical outcomes.

show abstract

“…Использованные штаммы были подробно изучены на различных клеточных моделях солидных опухолей in vitro и in vivo [17][18][19][20][21], однако ни в одном исследовании не рассматривались клеточные культуры опухолей лимфоидной природы. Мы использовали краткосрочные цитологически подробно охарактеризованные культуры клеток, стремясь получить максимально адекватную оценку способности панели непатогенных энтеровирусов реплицироваться на опухолевом субстрате.…”

Section: результаты и обсуждениеunclassified

The study of oncolytic viruses reproduction in organ cultures of human lymphoid tumors

et al. 2019

Self Cite

View full text Add to dashboard Cite

Онколитические вирусы являются перспективными средствами для лечения различных типов опухолей, в том числе злокачественных неходжкинских лимфом. С целью выявления наиболее эффективных кандидатов из широкой панели непатогенных противоопухолевых штаммов в работе проведено исследование их способности к репродукции в краткосрочных культурах клеток лимфоидных опухолей. Также опухолевые культуры клеток были охарактеризованы в отношении наличия на их поверхности специфических вирусных рецепторов CD54, CD55, CD155.

show abstract

Persistence of oncolytic Coxsackie virus A7 in subcutaneous human glioblastoma xenografts in mice in the context of experimental therapy

Cited by 4 publications

References 0 publications

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

Oncolytic Viruses in Tumor Therapy: The Russian Perspective

The study of oncolytic viruses reproduction in organ cultures of human lymphoid tumors

Contact Info

Product

Resources

About